{
    "title": "A unified Bayesian framework for interval hypothesis testing in clinical trials",
    "abstract": "arXiv:2402.13890v1 Announce Type: cross  Abstract: The American Statistical Association (ASA) statement on statistical significance and P-values \\cite{wasserstein2016asa} cautioned statisticians against making scientific decisions solely on the basis of traditional P-values. The statement delineated key issues with P-values, including a lack of transparency, an inability to quantify evidence in support of the null hypothesis, and an inability to measure the size of an effect or the importance of a result. In this article, we demonstrate that the interval null hypothesis framework (instead of the point null hypothesis framework), when used in tandem with Bayes factor-based tests, is instrumental in circumnavigating the key issues of P-values. Further, we note that specifying prior densities for Bayes factors is challenging and has been a reason for criticism of Bayesian hypothesis testing in existing literature. We address this by adapting Bayes factors directly based on common test sta",
    "link": "https://arxiv.org/abs/2402.13890",
    "context": "Title: A unified Bayesian framework for interval hypothesis testing in clinical trials\nAbstract: arXiv:2402.13890v1 Announce Type: cross  Abstract: The American Statistical Association (ASA) statement on statistical significance and P-values \\cite{wasserstein2016asa} cautioned statisticians against making scientific decisions solely on the basis of traditional P-values. The statement delineated key issues with P-values, including a lack of transparency, an inability to quantify evidence in support of the null hypothesis, and an inability to measure the size of an effect or the importance of a result. In this article, we demonstrate that the interval null hypothesis framework (instead of the point null hypothesis framework), when used in tandem with Bayes factor-based tests, is instrumental in circumnavigating the key issues of P-values. Further, we note that specifying prior densities for Bayes factors is challenging and has been a reason for criticism of Bayesian hypothesis testing in existing literature. We address this by adapting Bayes factors directly based on common test sta",
    "path": "papers/24/02/2402.13890.json",
    "total_tokens": 838,
    "translated_title": "一种统一的贝叶斯框架用于临床试验中的区间假设检验",
    "translated_abstract": "美国统计协会（ASA）关于统计显著性和P值的声明警告统计学家不要仅仅基于传统P值做出科学决策。声明阐明了P值存在的关键问题，包括缺乏透明度，不能量化支持零假设的证据，无法衡量效应的大小或结果的重要性。在本文中，我们证明了当与基于贝叶斯因子的测试一起使用时，区间零假设框架（而不是点零假设框架）有助于规避P值的关键问题。此外，我们注意到为贝叶斯因子指定先验密度是具有挑战性的，并且一直是现有文献中批评贝叶斯假设检验的原因。我们通过直接基于常见测试统计量调整贝叶斯因子来解决这一问题。",
    "tldr": "使用区间零假设框架和基于贝叶斯因子的测试，可以规避传统P值存在的关键问题，同时通过调整贝叶斯因子来解决先验密度的问题。",
    "en_tdlr": "By using the interval null hypothesis framework and Bayesian factor-based tests, key issues with traditional P-values can be circumvented, and addressing prior density criticisms by adapting Bayesian factors directly."
}